FindTrial
Sign In

Safety & efficacy assessment of products on skin

To evaluate the in-vivo safety and efficacy of topical skin care formulation on psoriasis patients - Not Applicable

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023151
Enrollment
33
Registered
2020-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Psoriasis Cream: Twice daily application on targeted psoriasis lesion for 28 days Control Intervention1: Not Applicable: Not Applicable

Sponsors

LaCorium Health International Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects should have psoriasis affecting <20% of Body Surface Area.

Exclusion criteria

Exclusion criteria: For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months Having refused to give his/her assent by signing the consent form Taking part in another study liable to interfere with this study Having history of cutaneous hypersensitivity Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products or to latex Ongoing use prohibited treatments (e.g. topical corticosteroids at least seven days on test site, systemic corticosteroids, oral anti psoriatic medication & Phototherapy at least four weeks.)

Design outcomes

Primary

MeasureTime frame
Safety & Efficacy assessment of productsTimepoint: T0, T7 days, T14 days & T28 days—

Secondary

MeasureTime frame
SafetyTimepoint: T0 days,T7 days, T14 days, T28 days—

Countries

India

Contacts

Public ContactMr Mohit Lalvani

Mascot Spincontrol India Pvt. Ltd.

siddheshwar@mascotspincontrol.in022-43349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026